Search This Blog

Thursday, February 21, 2019

Regeneron downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Yatin Suneja downgraded Regeneron Pharmaceuticals to Neutral after taking over coverage of the name. The analyst lowered his price target for the shares to $425 from $466.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)